Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu has reaffirmed a Buy rating on Molecular Partners, maintaining a price target of $12. The rating is based on the company's progress with its lead radiotherapeutic, MP0712, and upcoming catalysts expected in 2026. The firm is on track for initial SCLC data next year and has a strong cash position of approximately $100M, ensuring operational stability into late 2027. Zhu also notes the potential of the emerging pipeline, including MP0726 and the 225Ac program, which could enhance the company's value.
LifeSci Capital analyst Charles Zhu maintained a Buy rating on Molecular Partners today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Zhu has given his Buy rating due to a combination of factors, including steady execution on Molecular Partners’ lead radiotherapeutic, MP0712, and clear visibility toward key 2026 catalysts. The company is expanding clinical site activation, remains on schedule for initial SCLC data next year, and management sees room for accelerated dose escalation that could showcase safety and early efficacy signals.
Zhu also highlights the emerging pipeline value from MP0726 and the 225Ac program, where the DARPin platform offers flexibility to explore multiple isotopes and new targets by mid-2026. With roughly $100M in cash providing runway into late 2027, he views the balance sheet as sufficient to reach these data readouts, supporting an unchanged $12 price target and reinforcing his constructive outlook on the stock.